(VIANEWS) – The NASDAQ ended the session with Viking Therapeutics (VKTX) rising 15.16% to $36.68 on Friday while NASDAQ slid 0.82% to $15,775.65.
Viking Therapeutics’s last close was $31.85, 23.83% above its 52-week high of $25.72.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.12%.
Volatility
Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was 1.80%, 1.97%, and 3.96%.
Viking Therapeutics’s highest amplitude of average volatility was 4.26% (last week), 3.60% (last month), and 3.96% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Viking Therapeutics’s EBITDA is -26.32.
Moving Average
Viking Therapeutics’s value is way higher than its 50-day moving average of $18.76 and way higher than its 200-day moving average of $16.60.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be oversold (<=20).
More news about Viking Therapeutics (VKTX).
